Anika Therapeutics (ANIK) Current Leases (2019 - 2026)

Anika Therapeutics (ANIK) has reported Current Leases for 8 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Leases rose 6.61% year-over-year to $1.9 million in Q2 2026; TTM through Jun 2026 was $1.9 million, a 6.61% increase from a year earlier, with the FY2025 full-year figure at $2.1 million, up 6.99% from the prior year.
• Current Leases was $1.9 million for Q2 2026 at Anika Therapeutics, roughly flat from $1.9 million in the prior quarter.
• Over five years, Current Leases peaked at $2.3 million in Q3 2024 and troughed at $1.5 million in Q1 2022.
• A 5-year average of $2.0 million and a median of $1.9 million in 2026 frame the typical range for Current Leases.
• Across the five-year window, Current Leases surged 1184.03% in 2022 and declined 24.74% in 2025, its largest moves.
• Over 5 years, Current Leases stood at $2.1 million in 2022, then fell by 11.87% to $1.8 million in 2023, then increased by 4.98% to $1.9 million in 2024, then rose by 6.99% to $2.1 million in 2025, then decreased by 5.7% to $1.9 million in 2026.
• The last three Current Leases figures came in at $1.9 million (Q2 2026), $1.9 million (Q1 2026), and $2.1 million (Q4 2025), per Business Quant data.